Evaxion A/S (NASDAQ:EVAX) Posts Quarterly Earnings Results

Evaxion A/S (NASDAQ:EVAX) announced its earnings results on Thursday. The company reported $0.30 EPS for the quarter, reports.

Evaxion A/S Stock Performance

NASDAQ:EVAX traded down $0.18 on Friday, reaching $3.22. The company’s stock had a trading volume of 15,292 shares, compared to its average volume of 53,586. The firm has a market cap of $26.85 million, a PE ratio of -8.26 and a beta of 0.28. The business’s 50-day moving average price is $3.94 and its two-hundred day moving average price is $4.61. Evaxion A/S has a 1-year low of $1.20 and a 1-year high of $12.15.

Analyst Ratings Changes

A number of brokerages recently issued reports on EVAX. Weiss Ratings reiterated a “sell (d-)” rating on shares of Evaxion A/S in a report on Friday, January 9th. Maxim Group started coverage on Evaxion A/S in a research note on Thursday, February 19th. They set a “buy” rating and a $10.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $11.75.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of EVAX. Northwestern Mutual Wealth Management Co. acquired a new position in shares of Evaxion A/S during the 4th quarter worth approximately $38,000. Wesbanco Bank Inc. bought a new position in Evaxion A/S in the 4th quarter valued at about $48,000. Finally, SmartHarvest Portfolios LLC acquired a new position in Evaxion A/S during the fourth quarter valued at approximately $72,000. 11.04% of the stock is currently owned by institutional investors.

Evaxion A/S Company Profile

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.